OSLO, June 4 2025: Reference is made to the notice for the Annual General Meeting of EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), published on 28 May 2025.
The board of directors of EXACT-Tx wishes to clarify that a separate vote will be held for each of the candidates to the board of directors, in the Annual General Meeting to be held at 10:30 CEST on June 13, 2025.
Shareholders who wish to submit proxies or advance votes will be able to vote accordingly in the VPS or by specifying the same in the relevant form attached to the notice.
The documents are available at www.exact-tx.com.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
John M. Edminson, CFO
EXACT Therapeutics
Email: john.edminson@exact-tx.com
About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here:
www.exact-tx.com